Reporting to the Chief Scientific Officer, this role leads DMPK and bioanalytical strategy across nonclinical and clinical programs, operating as a hands-on scientific leader. We are looking for an accomplished DMPK and bioanalytical scientist with experience in PK study design, bioanalytical method development, and translational biomarker strategy. This person will support pharmacology and nonclinical toxicology programs, providing broader context across the nonclinical development portfolio. The ideal candidate brings deep scientific expertise and a hands-on approach and thrives in the fast-paced environment of a clinical-stage biotech where both scientific and strategic contributions are expected
Responsibilities
Lead DMPK and bioanalytical strategy across nonclinical and clinical programs, including PK, biomarker, and translational PD readouts
Lead method development, qualification, and validation for bioanalytical assays (GLP/GCP-compliant as required)
Design, execute, and oversee PK and PK-PD studies of tRNAs to evaluate delivery technologies (LNP and others) and biomarker effects
Manage and qualify CRO and external lab partners across bioanalytical and PK programs
Support nonclinical toxicology programs in collaboration with internal teams and CROs
Analyze, interpret, and present DMPK and translational biomarker data to internal leadership and external stakeholders
Author nonclinical sections of regulatory filings (e.g., IND) and briefing documents; support agency interactions and responses
Serve on the Research Leadership Team; represent DMPK and bioanalytical sciences in cross-functional program discussions
Manage and develop direct report(s); collaborate with the broader pharmacology team
Required Qualifications
PhD or equivalent in pharmacokinetics, pharmacology, biochemistry, analytical chemistry, or related field
8+ years of industry experience in DMPK, bioanalytical sciences, or closely related function
Experience with a range of bioanalytical methods and their development, qualification, and validation in both nonclinical and clinical contexts (e.g. mass spectroscopy, ELISA, NGS, etc.)
Experience with ligand binding assays and multiplex immunoassay platforms (e.g., MSD, Luminex) for cytokine, immunogenicity, and biomarker analysis
Demonstrated CRO oversight - vendor qualification, study monitoring, data review
Experience designing and overseeing PK and PK-PD studies for novel delivery modalities; LNP experience preferred
Experience in translational or clinical biomarker development, including assay strategy and fit-for-purpose qualification
Strong scientific writing skills - regulatory documents (e.g., IND nonclinical sections) and internal study reports
Experience supervising and developing scientists
Preferred Qualifications
Experience in rare disease, genetic medicine, or nucleic acid / RNA therapeutics
Familiarity with LNP platform biology and delivery landscape
Familiarity with GLP toxicology study design and ICH nonclinical guidelines
Experience operating in a cross-functional leadership role at a clinical-stage biotech
Experience with LC-MS/MS or related mass spectrometry platforms
About Alltrna
Alltrna is the first clinical-stage biotech company advancing tRNA medicines to address shared disease-causing mutations across many indications. The company’s initial therapeutic programs are designed to restore full-length protein production in diseases caused by premature termination codons (PTCs), collectively referred to as Stop Codon Disease, which affects approximately 10% of people with a rare genetic disease. Alltrna’s lead program, AP003, is a chemically modified, engineered tRNA oligonucleotide encapsulated in a clinically validated, liver-directed lipid nanoparticle. AP003 is being developed for the arginine-to-TGA (Arg-TGA) PTC in patients with liver Stop Codon Disease, including phenylketonuria, organic acidemias, and urea cycle disorders. Founded in 2018 by Flagship Pioneering, Alltrna has built an integrated platform to design, optimize, and deliver engineered tRNA therapeutics.
For more information, visit www.alltrna.com
The salary range for this role is $179,000 - $236,000. Compensation for the role will depend on a number of factors, including a candidate’s qualifications, skills, competencies, and experience. Alltrna currently offers healthcare coverage, annual incentive program, retirement benefits and a broad range of other benefits. Compensation and benefits information is based on Alltrna's good faith estimate as of the date of publication and may be modified in the future.
Privacy Notice for Applicants: When you apply for a role at Flagship Pioneering or one of its portfolio companies, we collect and use personal information you provide (such as your name, contact details, work history, and application materials) to evaluate your application, communicate with you, and comply with legal obligations. Your application data is processed through Greenhouse, our applicant tracking system, and may also be reviewed using AI-assisted screening tools. We do not sell your personal information. California residents have rights under the CCPA/CPRA including to know, delete, and opt out of the sharing of their personal information. If you are located in the EU or UK, we process your data under GDPR and you have rights to access, rectify, and erase your data. To exercise your rights or for questions, contact [email protected].
Skills Required
- PhD or equivalent in pharmacokinetics, pharmacology, biochemistry, analytical chemistry, or related field
- 8+ years of industry experience in DMPK, bioanalytical sciences, or closely related function
- Experience with a range of bioanalytical methods and their development, qualification, and validation in nonclinical and clinical contexts (e.g., mass spectrometry, ELISA, NGS)
- Experience with ligand binding assays and multiplex immunoassay platforms (e.g., MSD, Luminex) for cytokine, immunogenicity, and biomarker analysis
- Designing and overseeing PK and PK-PD studies for novel delivery modalities
- Demonstrated CRO oversight including vendor qualification, study monitoring, and data review
- Experience in translational or clinical biomarker development, including assay strategy and fit-for-purpose qualification
- Strong scientific writing skills for regulatory documents (e.g., IND nonclinical sections) and internal study reports
- Experience supervising and developing scientists
- LNP experience
- Familiarity with GLP toxicology study design and ICH nonclinical guidelines
- Experience operating in a cross-functional leadership role at a clinical-stage biotech
- Experience with LC-MS/MS or related mass spectrometry platforms
- Experience in rare disease, genetic medicine, or nucleic acid / RNA therapeutics
Flagship Pioneering Compensation & Benefits Highlights
The following summarizes recurring compensation and benefits themes identified from responses generated by popular LLMs to common candidate questions about Flagship Pioneering and has not been reviewed or approved by Flagship Pioneering.
-
Fair & Transparent Compensation — Feedback suggests salary bands are visible for many Boston/Cambridge roles and pay is considered competitive for key scientific and leadership positions. Transparency in postings supports expectations that offers align with local biotech norms.
-
Healthcare Strength — Feedback suggests medical, dental, vision, disability, life insurance, HSA options, and mental-health coverage are comprehensive and well-regarded. Multiple items are employer-verified, reinforcing confidence in core health benefits.
-
Parental & Family Support — Feedback suggests maternity/paternity leave and family leave are offered at meaningful levels. These programs sit alongside paid holidays, sick days, and PTO to support family needs.
Flagship Pioneering Insights
What We Do
Flagship Pioneering conceives, creates, resources, and develops first-in-category life sciences companies to transform human health and sustainability. Since its launch in 2000, the firm has applied a unique, hypothesis-driven innovation process to originate and foster more than 100 scientific ventures, resulting in over $30 billion in aggregate value. To date, Flagship is backed by >$3 billion of aggregate capital commitments, of which over $1.5 billion has been deployed toward the founding and growth of its pioneering companies alongside >$10 billion of follow-on investments from other institutions. The current Flagship ecosystem includes Denali Therapeutics (NASDAQ: DNLI), Evelo Biosciences (NASDAQ: EVLO), Moderna Therapeutics (NASDAQ: MRNA), Rubius Therapeutics (NASDAQ: RUBY), Seres Therapeutics (NASDAQ: MCRB), and Syros Pharmaceuticals (NASDAQ: SYRS).
.png)






